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ABSTRACT 
 
The CYP2D subfamily is the second most important subfamily of hepatic drug metabolizing 
CYPs. In mouse, there are nine CYP2D subfamily members, while humans have only one highly 
polymorphic CYP2D member, CYP2D6.  siRNA was used to repress the expression of multiple 
isoforms of mouse CYP2D in primary mouse hepatocytes with one siRNA construct.  Successful 
knockdown of CYP function by RNAi may allow for further study of CYP2D function.  Q-PCR 
demonstrated that male CD-1 mouse primary hepatocytes express Cyp2d10, Cyp2d11, Cyp2d22, 
and Cyp2d26; however the male specific and growth hormone-dependent, Cyp2d9, was not 
detected.  Four different siRNAs were designed; Cyp2d-KD1 and Cyp2d-KD2 target multiple 
CYPs while Cyp2d10-Design A and Cyp2d10-Design B only target Cyp2d10. 90% transfection 
efficiency with minimal cellular toxicity was achieved when Mirus-TKO transfection reagent 
was used. qPCR demonstrated that the construct designed to knockdown every CYP2D isoform, 
siRNA-KD1, showed knockdown efficiency of 50-70% and these results were reproducible with 
all four CYP2D members tested. Interestingly, a construct designed to knockdown all CYP2D 
isoforms except Cyp2d10, siRNA-KD2, induced Cyp2d10 expression 2.5-fold, presumably 
because of a compensatory response. Testosterone hydroxylation activity, tamoxifen metabolism 
and CYP2D activity were tested in scrambled and Cyp2d-KD1 siRNA treated hepatocytes using 
TLC, HPLC and CYP2D6-Glo
(tm)
 Screening Systems respectively. No metabolites differences 
were observed.   Overall, this study may provide a new tool for determining CYP2D’s role in 
xenobiotic metabolism, valuable information on how to design siRNA studies for silencing CYP 
subfamilies and ultimately may help in silencing mouse CYP2D’s within a humanized CYP2D6 
mouse model.   
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BACKGROUND 
 
Cytochrome P450s (CYPs) are enzymes that participate in many important metabolic 
processes including the detoxification of endogenous and exogenous chemicals. They 
perform a wide spectrum of reactions including hydroxylation, N-oxidation, 
sulfoxidation, epoxidation, N-, S-, and O-dealkylation, peroxidation, deamination, 
desulfuration and dehalogenation with the general purpose of making the substance more 
polar and water soluble. P450s metabolize endobiotics, such as steroids, bile acids, fatty 
acids, and prostaglandins, as well as xenobiotic compounds.  Ultimately, the metabolism 
of chemicals by CYPs (phase Ι) prepares the chemicals for phase ΙΙ conjugation (Cooper 
et al, 1965; Imai et al 1977; Champion et al, 1982; Nelson et al. 1996, Lewis, 1996; 
Bertz & Granneman 1997, Munro et al, 2007). 
 
For nomenclature purposes, the enzymes and genes encoding CYPs contain an Arabic 
numeral indicating the gene family, followed by a capital letter indicating the subfamily, 
and another numeral for the individual enzyme or gene. The italicized name refers to the 
gene. For example, CYP2D6 is the gene that encodes the enzyme CYP2D6 which is in 
family 2, subfamily D and the 6th isoform.  Human CYP names are capitalized (CYP2D6) 
and mouse CYP names are typically kept in lowercase (i.e. Cyp2d9).  CYPs sequences 
having greater than 40% identical at the amino acid level belong to the same family.  
While those that having sequences that are greater than 55% identical are in the same 
subfamily.  There are now more than 7700 named cytochrome P450 sequences. There is a 
 Nomenclature Committee that keeps track of and assigns new names (Nelson D.R. 
2004). The human CYP genes have been arranged into 18 families, 43 subfamilies, and 
57 isoforms; the mouse CYP genes have bee
and 102 isoforms (Nelson, 1999, Nelson D.R. 
 
In humans and mice, CYPs of families 1
xenobiotic metabolism, and m
1999). The activity of various CYP isozymes may 
either inducing the biosynthesis of an isozyme or by directly inhibiting the activity of the 
CYP. This is a major source of adverse drug interactions, in which 
activity affects the metabolism
drug interaction, the nonsteroidal antiestrogen
treatment and metabolized mainly by CYP2D6
(antidepressants; Fluoxetine paroxetine
risk because of reduce tamoxifen efficacy
 
The CYP2D subfamily plays an important role in the metabolism of xenobiotics and 
endobiotics. CYP2D isoforms have been identified in several mammalian species and are 
involved in the monooxygenation
desipramine), -blockers (e.g. propranolol), antiarrhythmics (e.g. sparteine),
(e.g. dextromethorphan and methadone) in the liver
Gonzalez, 1996). In humans, only
2 
n arranged into 13 families, 43 subfamilies, 
et al, 1993, 2004).  
-3 are the primary ones responsible for 
utations in them can affect drug metabolism (Nelson, 
also be increased or decreased by 
a change in a CYP’s 
 and detoxification of multiple drugs. An example of drug
 tamoxifen is used for breast cancer
. Patients using CYP2D6 inhibitors
, bupropion, and duloxetine ) can be at
.   
 of various chemicals including antidepressants (e.g. 
 and others 
 (Eichelbaum and Gross, 1990; 
 one functional isoform, CYP2D6, is expressed in 
et al 
-
 
 
  potential 
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various tissues including the liver, kidney, brain, placenta, breast, and lung (Niznik et al., 
1990; Romkes-Sparks et al., 1994; Carcillo et al., 1996; Hakkola et al., 1996; Guidice et 
al., 1997; Huang et al., 1997 and Nishimura et al., 2003). On the other hand, in mice, 
nine isoforms (Cyp2d9, Cyp2d10, Cyp2d11, Cyp2d12, Cyp2d13, Cyp2d22, Cyp2d26, 
Cyp2d34 and Cyp2d40) have been identified by genomic analysis.  It is thought that 
mouse Cyp2d22 is the ortholog of human CYP2D6 (Blume et al 2000 and Singh et al 
2009).    
 
In general, drug-metabolizing P450s are expressed at high levels in the liver, which 
controls the systemic levels of most drugs, xenobiotics and their metabolites. Orally 
administered xenobiotics pass through the intestine first before reaching the liver and has 
the capacity to metabolize many of these compounds through pathways mediated by 
P450s, including CYP2D6 (Prueksaritanont et al., 1995; Madani et al., 1999). The 
intestine may contribute to bioavailability and activation or deactivation of many 
xenobiotics. In addition to liver and intestine, CYP2D6 is expressed in kidney, and 
kidney tissue injury by some xenobiotics is dependent on renal P450 metabolism to toxic 
metabolites (Liu and Baliga, 2003; Liu et al., 2003). CYP2D6 is expressed in human 
brain (Siegle et al., 2001; Chinta et al., 2002; Miksys et al., 2002), suggesting the 
possibility of an endogenous function of CYP2D6 in the metabolism of neurochemicals. 
Although CYP2D6 activity has not been characterized yet in human brain, the kinetics of 
CYP2D-mediated dextromethorphan O-demethylase activity has been well described in 
rat brain tissues (Tyndale et al., 1999).  
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In mouse, Cyp2d10, Cyp2d11, Cyp2d13, Cyp2d22, Cyp2d26, and Cyp2d40 are 
expressed in liver. Cyp2d12, Cyp2d13, and Cyp2d34 are expressed in colon while 
Cyp2d12 is only expressed in kidney (Mouse Genome Informatics, 2010) (Table 1). 
Comparing CYP2Ds in mouse and human CYP2D6, recent studies showed that the cell-
specific expression of human CYP2D6 in liver, kidney, and intestine in humanized mice 
was similar to that reported in humans. While the expression patterns of mouse CYP2D 
proteins were similar to those in humans in liver and kidney but not in intestine. 
Moreover, human CYP2D6 was not detected in brain of transgenic mice while mouse 
CYP2D proteins were detected in brain (Ai-Ming and Robert, 2006). 
 
Table (1): Tissue expression of mouse Cyp2ds 
CYP2D(s)  Organ expression  
Cyp2d9  Liver/ Male specific  
Cyp2d10  Liver a  
Cyp2d11  Liver a  
Cyp2d12  Colon/Kidney a  
Cyp2d13  Liver/colon a  
Cyp2d22  Liver a  
Cyp2d26  Liver a  
Cyp2d34  Colon a  
Cyp2d40  Liver a  
a
 Information from Mouse Genome Informatics 
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The CYP2D subfamily is the second most important subfamily of liver CYPs in 
metabolizing xenobiotics and endobiotics, and plays a critical role in metabolism of more 
than 80 drugs in clinical use (Edeki , 1996) (Fig.1). CYP2D6 has been carefully studied 
using recombinant techniques, but the same cannot be said for the nine different mouse 
CYP2D members.  Furthermore, differences in metabolism between CYP2D members 
from human and mouse have not been thoroughly studied.  A mouse knockdown model 
would help determine CYP2D’s role in xenobiotic and endobiotic metabolism, and help 
determine differences between the mouse and human CYPs.  This important information 
could be used to better assess human risk because mouse data are used to estimate the 
adverse effects of drugs in humans.   
 
 
 
 
CYP3A4/5
CYP2D6
CYP2C9/10
CYP1A2
CYP2C19
CYP2E1
Proportion of Pharmaceuticals Metabolized by Individual CYP450 Isoforms
CYP3A4/5CYP2C8
CYP2C9
CYP2C19
CYP2E1
OTHER
CYP1A2
CYP2A6
CYP2B6
Major CYP450 Content in Human Liver
CYP2D6
Fig. 1: The role of CYP2D6 in drug metabolism: CYP2D6 is the second most important   
liver CYP involved in drug metabolism. 
6 
 
The CYP2D6 gene is highly polymorphic, and there are more than 90 known allelic 
variants to date (http://www.imm.ki.se/CYPalleles/CYP2D6.htm). About 5 - 10% of 
whites are poor metabolizers (Zanger et al., 2004), which might lead to individual 
variation in response to many drugs. There are several reports indicating increased 
disease risk and cancer association with genetic variation in CYP2D6.  For example, 
Parkinson’s disease (Kurth and Kurth, 1993), lung cancer, liver cancer, melanoma, and 
breast cancer all show associations with CYP2D6 polymorphisms (Agundez, 2004). 
CYP2D6 is responsible for metabolizing tamoxifen, a drug for breast cancer patients, to 
its most active form, endoxifen. Patients with specific functional CYP2D6 
polymorphisms who produce extremely low levels of active tamoxifen (poor metabolizer) 
are at increased risk of breast cancer recurrence because of lack of tamoxifen efficacy 
(Jin  et al, 2005; Hartman and Helft, 2007).  
 
Individuals with CYP2D6 polymorphisms may be poor metabolizers and predisposed to 
drug toxicity caused by some drugs (e.g. antidepressants or neuroleptics).  In contrast, 
other drugs (e.g. codeine) may not be ineffective due to lack of activation. A classical 
example of a chemical poorly metabolized by individuals with a CYP2D6 polymorphism 
is debrisoquine (Mahgoub et al., 1977). Poor metabolizers have an increased hypotensive 
response to the drug (Silas et al., 1977).  Poor metabolizers may also be more likely to 
develop plasma concentration related toxicity from impaired metabolism of phenytoin 
(Idle et al., 1980), nortriptyline (Bertilsson et al., 1980) and perhexiline (Shah et al., 
1982). 
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An example of excessive metabolizers is the high expression of CYP2D6 in many 
persons of Ethiopian and Saudi Arabian origin. CYP2D6 is not inducible, so these 
excessive metabolizers have multiple copies of the gene probably to cope with the high 
load of toxic alkaloids in their diet. These CYP2D6 enzymes therefore metabolize drugs 
such as antidepressants and neuroleptics very quickly making them ineffective. On the 
other hand, prodrugs will be extensively activated.  For example, codeine may be 
metabolized into vast amounts of morphine.  
 
The role of CYP2D6 and other CYPs in ADRs is critically important.  It is estimated that 
between 635,000 and 770,000 patients have a serious adverse drug reactions each year 
and approximately 106,000 people die from ADRs in the United States (Lazarou, 1998). 
Recent research suggests that pharmacogenetic data on P450 polymorphisms will 
ultimately explain approximately 10-20% of ADRs.  CYP2D6 is highly polymorphic, 
because of that, it is very important for physicians to consider a person's race or genetic 
background when drugs are given that may be metabolized differently by different 
populations. If there is no other way to get rid of these drugs from the body, poor 
metabolizers may be at life threatening risk.  
 
Toxicology testing is performed on animals with drugs, pesticides, and other chemicals to 
ensure the safety of people and the environment. However, the specificity of CYPs may 
vary greatly between species (Higgins et al, 2003) and may vary with gender due to the 
differing concentrations of sex hormones (David J. W. and Caitlin O, 2006).  For 
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example, CYP2D9 is expressed only in male mice because of male-specific pulsatile 
release of growth hormone (Kacew et al., 1995; Jarukamjorn et al 2006). Differences in 
the expression and function of the CYP2D members between humans and rodents may 
affect the outcome of toxicology studies (Baum and Strobel, 1997; Craig et al 2000).   
 
A CYP2D6-humanized transgenic mouse model was previously developed to evaluate 
and establish safe levels of chemical exposure and drug detoxification efficiency of 
human CYP2D6. (Corchero et al, 2001; Yu et al, 2004). In this model, the transgene 
includes the complete human wild-type CYP2D6 gene and its regulatory sequence and is 
present in the mice at 5 + 1 copies per haploid genome (Corchero et al., 2001).  Previous 
studies showed that debrisoquine hydroxylase activity is enhanced in CYP2D6 transgenic 
mice compared to wild-type mice indicating that CYP2D6 in humanized mice is 
functional (Corchero et al., 2001). Moreover, this transgenic mouse line has been used to 
establish that CYP2D6 is a 5-methoxyindolethylamine O-demethylase (Yu et al., 2003) 
which means that this transgenic mouse line could be used as model to test CYP2D6 
mediated metabolism. This model is believed to be a useful tool for investigating human 
CYP2D6-mediated metabolism of xenobiotics, and endogenous compounds, extrahepatic 
first pass metabolism by CYP2D6 and oral bioavailability of drugs. Also this model will 
help us understand the role of CYP2D6-mediated metabolism in organ-specific toxicity, 
pathologies, and disease. CYP2D6 expression was detected in liver, kidney, and intestine 
of the transgenic mice (Corchero et al., 2001, Miksys et al, 2005).   
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However, the humanized CYP2D6 transgenic mouse model still has the mouse CYPs 
present; therefore, these CYPs can complicate the conclusions drawn from the data when 
performing drug toxicity or metabolism studies. CYP2D knockout models are not 
available because of difficulty in knocking out all nine mouse CYP2D isoforms.  If one 
could knockdown multiple CYP2D-isoforms instead using siRNA techniques that would 
greatly enhance our ability to study the endogenous function of mouse CYP2Ds as well 
as use these models to study human CYP2D6.  However, prior to making a CYP2D 
knockdown mouse, we must determine if the model will be useful and if it is feasible.  
We aim to make an in vitro model system that reduces CYP2D RNA and protein 
expression so that in the future we can better understand CYP2D’s role in drug 
metabolism.   
 
RNAi:  (Fig.2).  RNA interference (RNAi) techniques make use of a specific cellular 
enzyme called Dicer that recognizes the double stranded RNA and chops it up into small 
fragments between 21-25 bps in length. The short double-stranded RNA molecules of 21-
25 bps in length can target mRNA with complementary sequence for degradation via a 
process termed RNAi. These short RNA fragments (called siRNA) for small interfering 
RNA, bind to the RNA-induced silencing complex (RISC). The RISC is activated when 
the siRNA unwinds and the activated complex binds to the corresponding complementary 
mRNA using the antisense RNA. The RISC contains an enzyme to cleave the bound 
mRNA and therefore causes suppression of gene expression. Once the mRNA has been 
10 
 
cleaved, it can no longer be translated into functional protein.  (Fire et al , 1998; 
Hammond et al 2000; Qiu et al 2005).  
 
 
 
 
 
 
In vitro studies showed that when short RNA duplexes are introduced into mammalian 
cells in culture, sequence-specific inhibition of target mRNA expression can be achieved 
Dicer
siRNA 
DUPLEX
RISK 
activation 
Target
mRNA
mRNA 
degradation
No protein expression
Fig.2:  RNAi: RNA interference works by forming a dsRNA that is processed by 
Dicer, loaded onto  RISC, and in turn forms a complex with specific 
homologous mRNA that is targeted for destruction; thereby suppressing 
translation.     
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without triggering an interferon response. These short synthetic dsRNAs act catalytically 
at sub-molar ratios and can cleave more than 95% of the target mRNA in the cell. In 
dividing cells, the RNA interference effect can be long-lasting and may be detectable 
after many cell divisions (Elbashir, S.M. et al. 2001, Caplen, N.J. et al 2001 and Sharp, 
P.A. 2001). siRNA could be used to control the redundant function of CYP2D isoforms 
and produce efficient knockdowns of CYP2D isoforms in vitro and in vivo.  This 
technology is much less expensive than targeting specific genes in embryonic stem cells 
to make knockouts as one or two constructs can be used to target multiple genes.  Here, 
we plan to use RNAi to knockdown the nine CYP2D subfamily members with a siRNA 
homologous to CYP2D sequence.  Ultimately, this could help us to study the exact 
function(s) of mouse CYP2D’s in drug metabolism. 
 
The main objectives of this study are to: a) Find and characterize an in vitro model 
system (cell line) that expresses mouse Cyp2d enzymes; b) Design and test siRNA 
constructs for their effectiveness at knocking down one or more murine Cyp2d isoforms; 
and c) Compare differences in metabolite profiles between control and CYP2D-
knockdown cells. 
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INTRODUCTION 
 
Cytochrome P450s (CYPs) are crucial endobiotic and xenobiotic phase I metabolism 
enzymes.  CYPs are expressed in most organs and during embryogenesis, but the 
majority of expression is within the liver (Abu-Abed et al., 2001; Otto et al., 2003; 
Raunio et al, 1995), the body’s primary detoxification organ.  The constitutive 
expression, inducibility, and activity of CYPs often explain differences in both the 
therapeutic effects and toxicity of drugs (Nishimuta et al, 2011, Yuu et al, 2011).  
 
In humans, the CYP2D subfamily has one functional isoform, CYP2D6 (Nelson et al. 
1996).  Although CYP2D6 only constitutes about 2% of total hepatic CYP, it is 
considered to be the second most important CYP involved in drug metabolism (Ingelman 
et al, 2001). CYP2D6 is involved in the metabolism of over 80 drugs in clinical use, 
including the selective serotonin reuptake inhibitors (SSRI), tricylic antidepressants, 
betablockers, opiates, neuroleptics, and antiarrhythmics (Zhou SF, 2009). CYP2D6 is 
highly polymorphic and there are more than 90 known allelic variants that cause 
subsequent defect in drug metabolism (Sharon et al., 2005). Individuals who have two 
homozygous copies for inactivating mutant CYP2D6 (i.e. both CYP2D6 alleles are non-
functional), are called poor metabolizers (PM) and in turn the metabolism of many drugs 
is slow in these individuals. PM are at risk of having a higher than expected serum 
concentrations in relation to the drug dose, and at higher risk of side effects. On the other 
13 
 
hand PM could have reduced effects when CYP2D6 metabolizes a “prodrug” into an 
active metabolite. Examples include codeine and tamoxifen (Zanger et al., 2004).  
Extensive metabolizers (EMs) have either one or two functional copies of the CYP2D6 
gene.  Some individuals are called ultrarapid metabolizers (UMs) because they may have 
three or more active CYP2D6 alleles as a result of a hereditary gene duplication that 
causes higher enzyme activity (Kirchheiner  et al., 2008). UM often have low serum 
concentrations and therefore receive less effect from the drug (Bradford LD, 2002, 
Ingelman-Sundberg et al. 1999, Kirchheiner et al 2004).  
 
In contrast to humans, mice have nine different mouse CYP2D genes; Cyp2d9, Cyp2d10, 
Cyp2d11, Cyp2d12, Cyp2d13, Cyp2d22, Cyp2d26, Cyp2d34 and Cyp2d40 (Nelson et 
al., 2004), most of them are expressed in livers (Sharon et al., 2005). There is limited 
data on the expression and function of each of the isoforms, although Cyp2d22 has been 
suggested to be the functional ortholog of human CYP2D6 (Blume et al., 2000 and Singh 
et al 2009).  Cyp2d9 is male specific and regulated by the STATs due to pulsatile growth 
hormone release (Wong et al, 1987 and Park et al, 1999).  Proteomic studies 
investigating CYP expression in the liver suggest that Cyp2d26 is expressed about 
equally or slightly more than Cyp2d10, which is expressed at greater levels than Cyp2d9 
(Sutton et al, 2010).   
 
Although mice have been used to assess drug and toxicant metabolism, considerable 
differences exist between the expression and catalytic activity of human and mouse 
14 
 
CYP2D isoforms (Bogaards et al. 2000).  For example, debrisoquine and bufuralol are 
metabolized by human CYP2D6 but not by mouse CYP2Ds (Ai- and Robert, 2006; Al-
Dabbagh et al., 1981; Kahn et al., 1985; Gonzalez et al., 1987; Masubuchi et al., 1997).   
 
Limited information about mouse-specific metabolism, strain and gender differences can 
cause problems in early drug development. Currently, a CYP2D6-humanized mouse 
model can be employed to determine the biotransformation of therapeutics by CYP2D6 
in vivo (Corchero et al., 2001; Yu et al., 2004), and it is assumed that the murine 
CYP2Ds will not interfere because of their considerably catalytic differences.  However, 
there is the possibility that the murine CYP2D’s will confound data using the humanized 
CYP2D6 mouse model. For example, CYP2D6 in human is a debrisoquine hydroxylase 
while mouse Cyp2d9 was first characterized as a testosterone 16a-hydroxylase. No 
common substrates have been reported for both CYP2D6 and Cyp2d9 enzymes (Gillian 
et al., 1998). CYP2D6 substrates debrisoquine and bufuralol metabolized at a much 
slower rate in mice. Moreover, Cyp2d22 metabolize codeine, dextromethorphan, and 
methadone to codeine N-demethylation, dextromethorphan O-demethylation and 
methadone N-demethylated respectively. While CYP2D6 metabolizes the same 
substrates to codeine O-demethylation, dextromethorphan N-demethylation and 
methadone is CYP2D6 inhibitor (Ai-M.Y and Robert L. H., 2006).   Therefore, increased 
knowledge of the metabolism of drugs by murine Cyp2d members can help reduce this 
uncertainty.    
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Because there are nine murine Cyp2d members, knocking them out by typical gene 
targeting may not be practical, and is extremely expensive.  Similarly, the role of Cyp2d 
enzymes in mouse hepatocytes is difficult to determine without specific inhibition of all 
of the Cyp2d members.  One potential way to inhibit multiple Cyp2d isoforms is to use 
RNAi.  However, using RNAi to repress several CYPs in a subfamily has not been 
previously done.   Therefore, the purpose of this study was to test whether the expression 
of multiple mouse Cyp2d isoforms could be repressed using single Cyp2d-siRNA 
construct.  
16 
 
MATERIALS AND METHODS 
 
Cell Culture:   
The mouse mammary tumor cell line, RIII/Pr1 was obtained from Strang Cancer 
Research Laboratory (NY, USA). The mouse hepatoma cell line, HEPA1C1C7, was 
purchased from ATCC (Manassas, VA, USA).  CD-1 mouse primary hepatocytes were 
purchased from either CellzDirect (Carlsbad, CA, USA) or Celsis in subsequent 
experiments (Chicago, IL, USA). All cells were incubated at 37◦C and 5% CO2. The 
immortal cell lines RIII/Pr1 and HEPA1C1C7 were maintained in DMEM (Dulbecco’s 
Modified Eagle’s Media) with 1% penicillin/streptomycin , 10% fetal bovine serum, 1% 
glutamine, 1% non-essential amino acids or Tropedo antibiotic mix from Celsis in 
subsequent experiments. Mouse primary hepatocytes were obtained at approximately 
750,000 cells / well in a 6-well plate and maintained in DMEM or Invitro GRO Hi 
medium from Celsis for 24hrs before transfection. 
 
siRNA design:   
ClustalW was used to align the nine CYP2D subfamily members, and shRNAs were 
designed against areas of high homology so that they would knockdown the expression of 
all or at least multiple CYP2D isoforms (Fig. 5).  In addition, two siRNA constructs 
homologous to Cyp2d10 and a scrambled construct were designed by SABiosciences 
(Frederick, MD, USA).  The scrambled construct was used as a negative control for the 
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down regulation of CYP2D expression. The sequence of each siRNA construct and 
estimated knockdown efficiency is available in Table 2.   
 
Table 2: DNA sequences of synthetically prepared siRNA constructs.     
Cyp Family  siRNA Construct *siRNA Scales and predicted 
efficiency 
Design A  TCCTGAGGTTCTTAATATGTT  18 
Design B  CCAAGGTCAGAAGTCCTTACT  43 
KD1  TCCAGAGATGGCAGACCAGGC  42 
KD2  CCTCTTCTTCACCTGCCTCCT  42 
 
*Predicted efficiency: Percentage of mRNA remaining in cells after siRNA directed 
cleavage  
 
Transfections:   
Mouse primary cells were transfected according to the manufacturer’s protocol in eleven 
6-well plates containing about 750,000 cells per well with siRNA using 2 µM,, 4 µM,  6 
µM or 12 µM siRNA using SureFECT® (SABiosciences), TransIT-TKO® and TransIT-
siQUEST® (Mirus Bio, Madison, WI, USA) transfection reagents.  The Label IT® 
siRNA Tracker Kits® (Mirus Bio) was used to label scrambled siRNA and assess the 
transfection efficiency of a siRNA construct.  8-well plate containing about 200,000 cells 
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per well was transfected by the labeled siRNA and then was visualized 12hrs hour later 
by confocal microscopy using a Zeiss LSM510 with optics for red and green 
fluorescence. AxioVision and Carl Zeiss software were used to extract pictures and 
compare fluorescence density in the transfected cells using FITC filter versus cells on 
bright field to determine how many cells were transfected and level of florescence 
between different transfection reagents. Transfection efficiency was determined by 
dividing the number of cells shown at FITC filter by the number of cells shown at bright 
field.  
 
Sample Preparation:  
When 90% confluent, mouse cell lines were collected while primary mouse hepatocytes 
were collected after 24 hours.  Cells were placed in Tri-Reagent® (Molecular Research 
Center, Cincinnati, OH, USA) for RNA extraction or placed in microsomal buffer (80% 
0.1 M phosphate buffer,  pH 7.5, 20% glycerol) (Jill W., 2003) for Western blotting.  All 
samples were stored at -80C until RNA extraction followed by DNAse (Promega 
Corporation, Madison WI) digestion to remove residual genomic DNA.  RNA was 
quantified spectrophotometrically at 260/280 nm and stored at –80oC.  Reverse 
transcription was performed to make cDNA using MMLV-RT, a dNTP mixture, and 
random hexamers, and stored at –20oC.   
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PCR:  
Primers designing:  
The updated list of the Cyp2d sequences was obtained from David Nelson’s Cytochrome 
P450 homepage (http://drnelson.utmem.edu/CytochromeP450.html ).  Gene-specific primer 
pairs were designed with the assistance of the Primer3 program available at 
http://wwwgenome. wi.mit.edu/cgi-bin/primer/primer3_www.cgi.  
  
PCR was conducted in 50 µL reactions containing 2.5 U Taq polymerase, 2.5 µL 10x 
buffer (Promega), 0.5 mm of each dNTP, 15 µM each gene-specific primer (Table 2) and 
0.5 µL (1 ng/µL) of template cDNA. Amplicons were amplified using a AB Veriti 96 
well PCR System thermocycler (Applied Biosystems inc.) using a protocol of 95 °C for 5 
min, followed by 40 cycles of 95 °C for 30 sec, empirically determined annealing 
temperature for 30 sec, 72 °C for 1 min, followed by a 10 min 70 °C final extension. 
Amplification of each primer set was confirmed on a 1.5% agarose gel electrophoresis. 
cDNA from male and female mouse livers were used as positive controls, and band sizes 
were estimated using a 100-bp ladder (Qiagen).   
 
Quantiative PCR 
Quantitiave Real-time PCR (qPCR) was performed as described previously (Muller et al., 
2002; Hernandez et al., 2007; Hernandez et al., 2009b) using gene specific primers 
(Table 3). PCR efficiency was determined from standard curves developed from 1:5 or 
1:10 serial dilutions of a cDNA composite of all samples. Amplifications were performed 
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in triplicate using a 96-well iQ5TM multicolor Real-Time PCR Detection System (Bio-
Rad, Hercules, CA,USA) with 0.25X SybrGreen  (SaBiosciences/Qiagen, Frederick, 
MD) to quantify gene expression. qPCR results were normalized to 18S rRNA 
expression. A minimum of forty cycles were run on all real time samples to ensure a log 
based growth curve. Quantification was done by taking the efficiency curve of the Q-
PCR reaction to the power of the threshold cycle (Ct) over the housekeeping gene 
(Muller et al., 2002).  Statistical significance of the qPCR data was determined by t-tests, 
or ANOVA followed by Tukey multiple comparison post-hoc test using GraphPad Prism 
software (La Jolla, CA). 
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Table 3:  CYP2D primers used for PCR and qPCR.   
Primers  Fragment 
size  
Annealing 
temp.  
Efficiency 
%  
Cyp2d9 
F:GAGCAGAGGCGATTCTCTGT  
R: CCCAGGTGGTCCTATTCTCA 
400 bp       57.5◦C NA a 
Cyp2d10  
F:  TCCACTGAATTTGCCACGC    
R:TCAGCACGGAGGACATGTTG           
101 bp  53.9◦C  90%  
Cy2d11  
F: CCTTCATGGCCATACTGGAT  
R: ATTCCCCTTGGCCTTTTCTA  
119bp  59◦C  113%  
Cyp2d22  
F: GGCGCTTCTCTGTGTCTACC  
R:  GTCCCAGGTCGTCTTGTGTT             
395 bp     61◦C  NA a 
Cyp2d22  
F:TGCCTAAGGTTTCCTGTTGG  
R:GTATCCCTGTTGGGTCATGG  
121 bp  51◦C  76%  
Cy2d26  
F:TTCAAAAGCCTGGAAGCAGT  
R:TCCACCAGAAGCAGGAAGAT  
100bp  59◦C  105%  
 
Primer sequences were obtained from other sources or designed using the Primer3 
program available at http://wwwgenome. wi.mit.edu/cgi-bin/primer/primer3_www.cgi.   
a
 Indicates a PCR primer and not used for qPCR  
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Western blots:   
 Microsomes were isolated by differential centrifugation in the presence of aprotonin, 
leupeptin, and PMSF as protease inhibitors.  The S9-fraction was prepared by spinning 
the cells with cytosol buffer at 10,000 rpm for 15 min, and the supernatant was collected.  
Protein concentrations were quantified using commercially available reagents (Bio-Rad, 
Hercules, CA) and stored at –80oC. Microsomal protein from wild-type mice was used as 
a positive control.  Western blots were conducted using 50-500 µg of microsomal protein 
separated electrophoretically on a 10% polyacrylamide gel (SDS-PAGE), transferred to 
nitrocellulose and incubated with a Rabbit anti-Human CYP2D6 polyclonal antibody 
(Chemicon International, Billerica, MA, USA).  The protein on the blots was detected by 
chemiluminescence using Immun-Star AP Chemiluminescent Protein Detection Systems 
(Bio-Rad Laboratories, Inc). The blots were scanned using Quantity One 4.6.5 1-D 
analysis software (Bio-Rad Laboratories Inc,). 
 
Testosterone hydroxylase assays 
Testosterone hydroxylase assays were used to measure Cyp2d activity as previously 
described (Hernandez et al., 2006). Mouse primary hepatocytes were transfected with 6 
µM of scrambled and Cyp2d-KD1 siRNA.  Twenty-four hours later, the cells were 
exposed for 2 hrs to 50 uM [14C] testosterone (300,000 dpm/ml), extracted with ethyl 
acetate, and testosterone metabolites were separated using thin-layer chromatography.  
Metabolites were visualized by autoradiography, cut out, and quantified with a LS5801 
liquid scintillation counter (Beckman, Fullerton, CA). 
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CYP2D6 Enzyme assay 
6-well plate of primary mouse hepatocytes were transfected with 6 µM of scrambled or 
Cyp2d-KD1 siRNA.  24 hrs later, the S9 fraction was isolated and stored at -80◦C.   
P450-Glo™ CYP2D6 Assay kits (Promega, Madison, WI, USA) was used to compare 
CYP2D activity between scrambled and Cyp2d-KD1 siRNA treated hepatocytes. The 
procedures were done according to the manufacture protocol.  
 
Tamoxifen Metabolism and HPLC 
Twenty-four hours after siRNA transfection in 6-well plates with scrambled and Cyp2d-
KD1 constructs, the primary hepatocytes were treated with 500mM tamoxifen (Sigma-
Aldrich, St. Louis, MO, USA). Cells and media were collected 2hrs later and stored at -
80°C.  Deconjugation was done by adding 20 units/ml of β-Glucuronidase  (from bovine 
liver) and Sulfatase (from Helix pomatia), and incubating for 2hr in a shaking water bath 
at 37C.  Extraction of the metabolites was done as described by (Kyung et al., 2003).  
Internal standard of tamoxifen, 4-hydroxy-tamoxifen and endoxifen were made to 
determine the extraction efficiency. Standard were filtered (0.22 µm PTFE filter; Fisher 
Scientific, Pittsburgh, PA, USA) and metabolite concentrations were measured using 
Reverse Phase-HPLC. Standards for all compounds were prepared in methanol and stored 
at -20°C prior to analysis. Tamoxifen, 4-hydroxy-tamoxfen and endoxifen, were analyzed 
using a Waters 1525 binary reverse phase-high phase liquid chromatography pump 
(HyperSelect Gold C18, 5 µm, 120 Å particle size, 250 mm X 4.6 mm with guard 
column; ES Industries Chromega Columns, West Berlin, NJ). The mobile phase consisted 
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of 35% acetonitrile and 65% 20 mM potassium phosphate buffer (pH=3) over 70 minutes 
at a flow rate of 1 ml/min. Chemical detection was determined at excitation wavelength 
of 256 nm and an emission wavelength of 380nm.  The detection limit for 4-hydroxy-
tamoxifen and endoxifen were 0.005 and 0.0025 mg/ml, respectively.     
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RESULTS AND DISCUSSION 
 
Expression of Cyp2d isoforms in cell culture  
Two different immortal murine cell lines and primary mouse hepatocytes were used to 
assess Cyp2d isoforms expression. The mouse hepatoma cell line, HEPA1C1C7, did not 
express any of the Cyp2d isoforms tested by Western blotting or PCR.  The murine 
mammary tumor derived cell line, RIIIPrI, expresses Cyp2d22 but no other Cyp2d 
members were detected (Fig.3, b).  Protein expression was not detected by Western 
blotting (Fig.3, a).  Therefore, we determined that murine immortal cell lines did not 
contain enough CYP2D for subsequent knockdown by siRNA.      
Mouse primary hepatocytes from male CD-1 mice showed expression of Cyp2ds as 
demonstrated by western blotting analysis (Fig.4b).  Furthermore, PCR analysis 
demonstrated that Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26 are expressed in mouse 
hepatocytes (Fig. 4a). However, Cyp2d9, a male specific CYP, was not expressed in the 
male primary hepatocytes.  cDNA from the livers of wild-type male (WT-M) mice 
expressed Cyp2d9, but wild-type female (WT-F) did not show expression of this CYP. 
Cyp2d9 expression is controlled by the release of growth hormone in a pulsatile fashion 
(Gianpaolo and Walter, 2011).  Therefore, we hypothesized that the loss of pulsatile 
growth hormone release from the anterior pituitary in cultured cells caused the loss of 
Cyp2d9 expression from the male primary hepatocytes within 48 hours.  This suggests 
that male sexual dimorphism mediated by growth hormone is difficult to sustain in 
culture.  
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HEPAIC     RΙΙΙPrΙ WT-M
Cyp2d26Cyp2d11
RΙΙΙPrΙ WT-M RΙΙΙPrΙ WT-M Ladder
Cyp2d26
Ladder    HEPAIC     WT-M
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RΙΙΙPrΙ WT-M            Ladder
50 kDa
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B 
Fig. 3: CYP2Ds expression in murine cell lines.  (A) Protein expression of CYP2Ds in 
mouse hepatoma cell line HEPA1C1C7 and RIIIPrI by Western blotting with 
500 µg protein.  Microsomes from wild-type male mouse livers (WT-M) were 
used as positive controls.  (B) PCR detection of Cyp2ds in the HEPA1C1C7 
and RΙΙΙPrΙ cell lines.  
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Fig. 4: Detection of murine CYP2D isoforms in mouse primary hepatocytes.  (A) PCR 
detection of Cyp2d9, Cyp2d10, Cyp2d11, Cy2d22 and Cy2d26 in primary 
hepatocytes. Hep = primary hepatocytes; WT = wild-type; M = male; F = female.  
(B) Western blot using polyclonal antibody for CYP2D in mouse primary 
hepatocytes compared to microsomes from WT-M mouse livers.   
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CYP2D similarity and siRNA design  
There are nine CYP2D isoforms in mouse, and some probably have redundant functions. 
Multiple Sequence Alignments (ClustalW) indicate that there are two areas of the 
CYP2D isoforms that are highly homologous, and therefore it was possible that one 
siRNA could knockdown the expression of all nine isoforms (Fig. 5).  We designed 
siRNA to target all nine isoforms based on these alignments and called them Cyp2d-KD1 
and Cyp2d-KD2.  Cyp2d-KD1 is expected to repress the expression of all of the Cyp2d 
isoforms, while Cyp2d-KD2 is expected to target all but cyp2d10 because of a single 
nucleotide mismatch in the middle of the sequence. To evaluate and compare our siRNA 
designs to siRNAs specific to only one gene; two siRNAs designed to target Cyp2d10 
were purchased from SABiosciences, and named Cyp2d10-desgin A and Cyp2d10-design 
B (Table 3). siRNA scales (http://gesteland.genetics.utah.edu/siRNA_scales/) was used to 
estimate the level of Cyp2d expression following transfection with each siRNA construct 
(Mateeva  et al 2007) (Table 3). 
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  Fig.5: Target areas of each of the siRNAs.   Homologous areas of each of the CYP2D 
isoforms to each of the siRNAs were determined by CLUSTALW.  CYP2D-KD1 
and CYP2D-KD2 were purposely designed to target multiple CYP2D isoforms.   
 
  
Cyp 
Family 
 
Cluster sequences of Mus musculus Cyp2ds mRNA 
 
Cyp2d-KD1 
 
Cyp2d9        TCATAGGGCAGGTGAGGCATCCAGAGATGGCAGACCAGGCCCACATGCCC 1146 
Cyp2d12       TCATAGGGCAGGTGAGGCATCCAGAGATGGCAGACCAGGCCCACATGCCC 1120 
Cyp2d10       TCATAGGGCAGGTGCGGCATCCAGAGATGGCAGACCAGGCTCGTATGCCC 1141 
Cyp2d11       TCATAGGGCAAGTGCAGCATCCAGAGATGGCAGACCAGGCTCGCATGCCC 1146 
Cyp2d34       TCATAGGGCAGGTGCGGTGTCCAGAGATGGCAGACCAGGCCCGCATGCCC 1121 
Cyp2d26       TCATAGGGCACGTGCGGCATCCAGAGATGGCAGACCAGGCCCGCATGCCC 1143 
Cyp2d22       TCATAGGGCAGGTGCAGTGTCCAGAGATGGCAGACCAGGCTCGCATGCCC 1110 
Cyp2d13       TCATAGGGCAGGTGCGGTGTCCAGAGATGGCAGACCAGGCCCACATGCCC 1143 
Cyp2d40       TCATAGGGCAGGCACGGCGTCCAGAGATGGCAGACCAGGCCCGCATGCCC 597 
 
Cyp2d-KD2 
 
Cyp2d9       CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCTGATG 1495 
Cyp2d12      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCTGATG 1469 
Cyp2d10      CCTCTTCTTCACGTGCCTCCTGCAGCACTTTAGCTTCTCAGTGCCCAATG 1490 
Cyp2d11      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCATCTCAGTGCCTGATG 1495 
Cyp2d34      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCAGCTG 1470 
Cyp2d26      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTGCCCGATG 1492 
Cyp2d22      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCATCTCAGTGCCCGATG 1459 
Cyp2d13      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTTAGTGCCTGCTG 1493 
Cyp2d40      CCTCTTCTTCACCTGCCTCCTGCAGCGCTTTAGCTTCTCAGTACCGGATG 946 
 
Cyp2d10- 
Design A 
 
  Cyp2d9  TCCTGAGGTTCTTAATGCATTCCCGATACTCTTGCGTATCCCAAGGCTGGCTG 796  
  Cyp2d12 TCCTGAGGTTATTAACACATTCCCGATACTCCTGCACATCCCAAGGCTGGCTG 770  
  Cyp2d10 TCCTGAGGTTCTTAATATGTTCCCCATACTCCTGCGCATCCCAGGACTGCCTG 791  
  Cyp2d11 TCCTGGGGTACTTAATGAGTTCCCAATATTCCTGCGCATCCCAGGGCTGGCTG 796  
  Cyp2d34 TCCTGGGGTTCTTAACACGTTCCCAATACTCCTGCGAATCCCAGGGCTGGCTG 771     
  Cyp2d26 CGGAGAGGTGCTGAATGCCATCCCAATGCTACTACACATCCCTGGTTTGCCTG 793  
  Cyp2d22 ACCCATGTTCCTGAATGTGTTCCCGATGCTCCTGCGCATCCCGGGGCTGGTTG 760  
  Cyp2d13 TCCAGAGGTTCTGAACACATTTCCAATTCTCCTGCACATCCCAGGGTTGGCTG 793  
  Cyp2d40 TTACAAGGTTGTGAAGATGTTCCCAATTGTCCTGCGCATCCCAGGGTTGGCTG 247  
 
Cyp2d10- 
Design B 
 
   Cyp2d9   ACAAGGCCCTCCAAGGTCAGAAGTCCTTCATCGCCATACTGGATAACCTG 846  
   Cyp2d12  ACAAGTTCCTGCAAAGTCAGAAGTCCTTCATCGCCATAGTGGATAACCTG 820  
   Cyp2d10  GGAAGGTCTTCCAAGGTCAGAAGTCCTTACTGGCCATAGTGGAGAATCTG 841  
   Cyp2d11  ACATGGTCTTCCAAGGTCAGAAGTCCTTCATGGCCATACTGGATAACCTG 846  
   Cyp2d34  ACATGGTCTTCCAAAGTCAGAAGACCTTCATGGCCATACTGGATAACCTA 821  
   Cyp2d26  ATAAAGCCTTCCCCAAGCTGAATTCATTCATAGCCTTAGTGAATAAGATG 843  
   Cyp2d22  GCAAGGTCTTCCCTGGGAAAAGGGCCTTTGTTACCATGTTGGATGAGCTG 810  
   Cyp2d13  ACAAAGTCTTCCCTGGGCAAAAGACATTTCTCACCCTGGTAAATAAGCTG 843  
   Cyp2d40  ATAAAATCTTCCCTGGGCAAAAGACATTTCTCACCATGGTGGATAAGCTG 297  
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Knockdown of Cyp2d isoforms by siRNA: 
In our first trial, primary hepatocytes were transfected with 2 µM or 6 µM of siRNA for 
each the siRNAs (including a scrambled construct) using SureFECT transfection reagent. 
qPCR was used to evaluate the expression of Cyp2d10, Cyp2d11, Cyp2d22 and 
Cyp2d26. Cyp2d10 expression was significantly down regulated by siRNA with 
Cyp2d10-design A and Cyp2d-KD1 at both 2 µM and 6 µM in a dose dependant manner.  
Cyp2d10-design B only reduced Cyp2d10 expression at 6 µM. The percent knockdown 
ranged from 10-50% for each of these siRNAs (Fig. 6).  In contrast, Cyp2d10 was up-
regulated when Cyp2d-KD2 was transfected into hepatocytes at 2 µM and 6 µM (Fig. 6).  
Cyp2d-KD2 was designed to knockdown the expression of all of the CYP2D members 
except Cyp2d10, indicating that the loss of the other Cyp2d members may have caused a 
compensatory reaction that led to an increase in Cyp2d10 expression.  Currently, the 
transcription factors that regulate Cyp2d10’s inducibility are not known and it has been 
suggested that most Cyp2d isoforms are not inducible (Tomohiro et al., 2000); however, 
this data appears to indicate that Cyp2d10 is inducible.  Overall, with the exception of 
Cyp2d-KD2, all of the designs were able to knockdown Cyp2d10 expression at about the 
same range, but none repressed expression greater than 50%.    
 
Cyp2d11 mRNA expression was not significantly repressed by any of the siRNA designs; 
however, trends suggest that all of the constructs showed some ability to reduce Cyp2d11 
expression about 50% with Cyp2d-KD1 showing the greatest potency (Fig. 7).   
Similarly, the expression of CYP2D22 (Fig. 8) and Cyp2d26 (Fig. 9) were not 
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significantly repressed by any of the siRNA constructs.  However, two trends were 
observed.  The siRNA constructs designed to repress the expression of all of the Cyp2d’s 
were more efficacious than those designed to only repress the expression of Cyp2d10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Relative expression of CYP2D10 in mouse primary hepatocytes that were 
transfected with 2µM and 6µM siRNA design A (A), design B (B), KD1 (C), and 
KD2 (D) compared to hepatocytes transfected with scrambled siRNA.   An 
asterisk indicates statistical significance (p < 0.05) by ANOVA followed by 
Tukey multiple comparison post-hoc test (n = 3).   
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Fig.7: Relative expression of CYP2D11 in mouse primary hepatocytes that were 
transfected with 2µM and 6µM siRNA design A (A), design B (B), KD1 (C), and 
KD2 (D) compared to hepatocytes transfected with scrambled siRNA.   No 
significant differences (p < 0.05) were detected by ANOVA followed Tukey 
multiple comparison post-hoc test (n = 3).   
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Fig. 8: Relative expression of CYP2D22 in mouse primary hepatocytes that were 
transfected with 2µM and 6µM siRNA design A (A), design B (B), KD1 (C), and 
KD2 (D) compared to hepatocytes transfected with scrambled siRNA.   No 
significant differences (p < 0.05) were detected by ANOVA followed by compared 
to scrambled post-hoc test (n = 3).   
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Fig.9: Relative expression of CYP2D26 in mouse primary hepatocytes that were 
transfected with 6µM siRNA design A (A), design B (B), KD1 (C), and KD2 (D) 
compared to hepatocytes transfected with scrambled siRNA.   No significant 
differences (p < 0.05) were detected by Student’s t-test (n = 3).   
 
 
 
Cyp2d26
SC 6 A  6
0.0
0.4
0.8
1.2
siRNA-A
R
e
la
ti
v
e
 
e
x
p
re
s
s
io
n
SC 6 B 6
0.0
0.4
0.8
1.2
siRNA-B
R
e
la
ti
v
e
 
e
x
p
re
s
s
io
n
SC 6 KD1  6
0.0
0.4
0.8
1.2
siRNA-KD1
R
e
la
ti
v
e
 
e
x
p
r
e
s
s
io
n
SC 6 KD2  6
0.0
0.4
0.8
1.2
siRNA-KD2
R
e
la
ti
v
e
 
e
x
p
r
e
s
s
io
n
A B
C D
35 
 
The data indicates that Cy2d-KD1 and Cyp2d-KD2 were able to show some loss of the 
expression of multiple CYP2Ds in the primary hepatocytes as planned; however, the 
expression loss was often not significant and weaker than anticipated.  Cyp2d-KD2 also 
caused an increase in the expression of Cyp2d10 probably because of a compensatory 
reaction, and therefore this siRNA construct is not useful for knocking down the 
expression of all hepatic CYP2D members.  Interestingly, the two designs for Cyp2d10 
worked specifically based on statistically analysis; however, subjectively there appears to 
be a consistent down-regulation of other isoforms such as Cyp2d11 and Cyp2d22.  Given 
the high homology between the Cyp2d10 and Cyp2d11 this was expected.   
 
Based on these results, we determined that the best overall siRNA construct for 
repressing multiple Cyp2d isoforms was Cyp2d-KD1.   However, expression was not 
repressed as much as desired.  These results suggested that optimizing the transfection by 
increasing the siRNA dose or using multiple siRNA might be necessary to obtain higher 
knockdown efficiency.  
 
Subsequently, primary hepatocytes were transfected with a higher concentration of 
Cyp2d-KD1 siRNA (12 µM), and with a mix of Cyp2d10-design A, Cyp2d-KD1 and 
Cyp2d-KD2 in order to achieve greater repression of CYP2D expression. However, 
knockdown efficiency was dramatically decreased with higher concentrations of siRNA 
suggesting that multiple siRNA could be competing for processing by Dicer/RISC and 
inhibiting the deactivation initiated by Cyp2d-KD1. However, we consider it a more 
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likely alternative that 12 µM of siRNA was too great for the cells and elicited toxicity or 
maybe an interferon response (Scott et al., 2007) leading to down-regulation of many 
genes in the cells transfected with scrambled or Cyp2d-targeted siRNAs, and an inability 
to accurately quantify Cyp2d isoforms.   
 
Transfection efficiencies and toxicity:   
Based on our marginal first set of results with 2 µM and 6 µM siRNA and our poor 
results with 12 µM siRNA, we hypothesized that poor transfection efficiency in primary 
hepatocytes is the problem and we should try different transfection reagents. Our first set 
of siRNA transfection produced marginal to poor results with great variability, potentially 
because of poor transfection efficiency in the primary mouse hepatocytes.  Therefore, we 
compared transfection efficiency between three different transfection reagents:  The 
reagents we tried were SureFECT, the first transfection reagent we used but one 
optimized for immortal cells, and TransIT-TKO and TransIT-siQUEST produced for use 
with primary cell culture.  
 
Primary mouse hepatocytes were transfected with fluorescence labeled scrambled siRNA 
and transfection efficiency examined based on the number of cells transfected 
(fluorescence using FITC filter) divided by the total number of cells (in Bright light 
field).  Nearly 100% transfection efficiency was achieved by using TransIT-siQUEST 
transfection reagent (Fig. 10).  Lower transfection efficiencies were observed following 
transfection with TransIT-TKO and SureFECT, both appeared 90% effciency (Fig. 10).  
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However, cellular debris consistent with cellular toxicity was observed in the cells 
transfected with TransIT-siQUEST and SureFECT but not TransIT-TKO (Fig. 10). 
     
 
Fig. 10: Comparison of the transfection efficiency of three different transfection reagents 
in primary mouse hepatocytes; TransIT-TKO and TransIT-siQUEST from Mirus 
Bio and SureFECT from SABiosciences were used to transfect cells with 
fluorescence labeled siRNA probes and visualized using confocal microscopy 
(40 x objective).. TransIT-seQUEST had the best transfection efficiency, but this 
reagent also caused significant toxicity and repression of CYP2D isoforms was 
not observed.  TransIT-TKO had reasonable transfection efficiency with little 
toxicity, while SureFECT appeared to work well, but the relatively high 
efficiency led to high toxicity.   
 
Primary hepatocytes were transfected with 6 µM siRNA and either Cyp2d-KD1 or 
scrambled siRNA using TransIT-siQUEST transfection reagent because of its high 
transfection efficiency. However, upon collecting the cells 24 hours after transfection, 
most of the cells were poorly attached to the plate and appeared dead.  RNA extracted 
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from the cells was of poor quality and the level of Cyp2d10 expression did not vary 
between scrambled and Cyp2d-KD1 treated hepatocytes.  
 
TransIT-TKO transfection reagent was the only reagent that did not cause an increase in 
cellular debris, and therefore subsequent studies were performed with this transfection 
reagent. The first set of transfections performed with TransIT-TKO were done to serve 
the dual purpose of testing whether this transfection reagent worked well, and to test 
whether the scrambled siRNA construct interfered with Cyp2ds expression.   A 6-well 
plate of primary hepatocytes were mock transfected, transfected with 6µM of scrambled 
siRNA, or transfected with Cyp2d-KD1 using TransIT-TKO transfection reagent (n = 2).  
The mRNA expression of Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26 did not vary 
between mock transfected and scramble-transfected hepatocytes indicating that the 
scrambled siRNA has no adverse interfering actions on the cells. In comparison, Cyp2d-
KD1 significantly repressed the expression of Cyp2d11 and Cyp2d22, and if not for the 
high variability of Cyp2d10 expression in the mock transfected cells Cyp2d10 would 
have been significantly repressed (Fig.11).  Overall, Cyp2d-KD1 in conjunction with 
TransIT-TKO showed an improved knockdown efficiency of 50-70%. Large variability 
of CYP2D expression was observed in the wild type primary hepatocytes indicating that 
CYP2D polymorphism could be exist in mice.  Further studies are still required to test the 
polymorphism in mouse Cyp2ds. Different in-breds and batched samples from different 
places would be the best way to check the reason behind the variability of enzymes 
activity.  
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Fig. 11: Relative expression of CYP2D in untreated (UT), scrambled (SC) and KD1 
treated primary mouse hepatocytes.  UT are cells that were mock-transfected, SC 
are cells that were transfected with the scrambled siRNA construct, and KD-1 
are cells that were transfected with the KD-1 siRNA construct.   An asterisk 
indicates statistical significance (p < 0.05) by ANOVA followed by Tukey 
multiple comparison post-hoc test (n = 2).   
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Primary mouse hepatocytes were used in metabolism study as an in vitro model system 
for detecting metabolites difference between wild type and knockdown.  To make sure 
this work is repeatable and to ensure knockdown occurs during the metabolism assays, 
four 6-well plates of mouse primary hepatocytes were transfected with 6 µM of Cyp2d-
KD1 and scrambled siRNA using the TransIT-TKO transfection reagent.  One plate used 
for RNA extraction and qPCR, while the other three plates used for detecting CYP2D 
activity in metabolizing three different substrates. qPCR results showed that Cyp2d-KD1 
was able to significantly knockdown the expression of all the hepatic Cyp2d isoforms 
tested, Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26, at 6 µM with a knockdown 
efficiency of 50-70% (Fig. 12).  Overall, an improvement over the first set of experiments 
in both efficiency of knockdown and the number of genes significantly repressed was 
observed.  This demonstrates that of the three transfection reagents used TransIT-TKO is 
the best based on lower toxicity coupled with reasonable transfection efficiencies.   
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Fig.12: Repression of CYP2D expression in primary hepatocytes is repeatable using the 
TransIT-TKO transfection reagent and the KD1 construct. An asterisk indicates 
statistical significance (p < 0.05) by Student’s t-test (n = 3).   
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Testosterone hydroxylation assay  
Cyp2d-mediated changes in testosterone metabolism were investigated after transfection 
with the scrambled and Cyp2d-KD1 constructs.  Mouse Cyp2ds have sterio- and regio-
specifically hydroxylate testosterone at the 16α-position (Baldwin and LeBlanc, 1992). 
The data showed no significant difference in 16α-hydroxylation between scrambled and 
Cyp2d-KD1 siRNA treated cells (Fig. 13). There are several potential explanations for 
the Cyp2d-KD1 construct to not reduce 16α-hydroxylation.  For example, while Cyp2d 
mRNA levels are lower after 24- hours, a significant RNAi-mediated drop in protein 
levels may take 48-72 hours (Mike Byrom, 2004; Francesco et al., 2006).   Cyp2d9, 
which is a male specific isoform responsible for testosterone metabolism, was not 
expressed in detectable level in vitro, and therefore Cyp2d’s role in 16a-hydroxylation 
may have been minimized. This in turn could have caused allowed for other CYPs such 
as the Cyp2b’s or Cyp2c’s to play a primary role in 16α-hydroxylation of testosterone in 
vitro.  Lastly, the expression of most CYPs in primary hepatocytes drops precipitously 
during monolayer culture; however, Cyp2b9 expression does not drop and Cyp2b10 
expression increases 15X (Karen M. et al., 2009). Therefore, these Cyps may have 
performed most of the 16a-hydroxylation and in turn the effects of Cyp2d-KD1 on Cyp2d 
activity were concealed. 
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Fig. 13: Autoradiograph of [14C] hydroxytestosterone metabolites following thin layer 
chromatography (TLC) 
 
 
P450-Glo(tm) enzyme assay 
Luminogenic CYP2D6 substrate was incubated in S9 fractions from primary hepatocytes 
from Cyp2ds enzyme activity was tested in S9 fractions prepared from scrambled and 
Cyp2d-KD1 treated primary hepatocytes by incubating luminogenic CYP2D6 substrate. 
The results showed no significant difference was observed in the Cyp2ds activity 
between scrambled and Cyp2d-KD1 siRNA transfected cells (Fig. 14). This enzyme 
assay was designed for CYP2D6 activity which could not be the same for mouse 
CYP2Ds.  Excessive esterase activity in cell model would interfere with the substrate 
stability. This could explain the low level of enzyme activity in the tested cells. 
KD1                        SC                   Control
16a-hydroxytestosterone
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Fig. 14: P450-Glo(tm) enzyme assay: Cyp2d enzyme activity from the S9 fraction of 
scrambled- (SC; control) and Cyp2d-KD1 (KD1) - treated primary hepatocytes 
when incubated with luminogenic CYP2D6 substrate.   
 
Tamoxifen metabolism  
Tamoxifen is in part metabolized by CYP2D6 (Vincent et al., 2008) (Fig. 15).  
Tamoxifen is metabolized to 4-hydroxytamoxifen by CYP2D6 as well as other CYPs, 
and in turn can be metabolized by CYP3A4 to Endoxifen.  Tamoxifen is also metabolized 
by CYP3A4 as well as other CYPs to N-desmethyltamoxifen (NDM-tamoxifen), and in 
turn metabolized primarily by CYP2D6 to endoxifen.        
 
 
 
  
 
 
 
 
 
 
 
 
 
After RNAi incubation, the metabolites of tamoxifen were measured by HPLC to test 
whether Cyp2d-KD1 perturbed Cyp2d
hydroxytamoxifen standard elutes at 34 minutes; h
metabolite that eluted at 37-
little interest because it is not produced by CYP2Ds.  
metabolite measured by HPLC
the other metabolites.  Endox
reaction.      
 
The data showed that there is no significant difference 
scrambled and Cyp2d-KD1 siRNA treated hepatocytes 
knockdown model to metabolize the tamoxifen as efficient as wild type cells could be 
Fig. 15:  Tamoxifen metabolism by CYPs.   Tamoxifen is metabolized by several 
CYPs.  The metabolism of NDM
performed by CYP2D6 in humans.   
45 
-mediated metabolism of tamoxifen. The 4
owever, we primarily observed a 
39 minutes.  NDM tamoxifen was not observed and was of 
Endoxifen was clearly the 
 as approximately 30X more endoxifen was detected than 
ifen is the ultimate phase I metabolite produced during this 
in tamoxifen metabolism between 
(Fig. 16). The ability of the 
-tamoxifen to Endoxifen is primarily 
 
-
dominant 
 
46 
 
explained by the possibility of other mouse CYPs in metabolizing the substrate. Another 
possibility is that the ideal knockdown efficiency was not achieved yet so the remaining 
CYP2D protein that is still expressed is able to metabolize the drug.  
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Fig. 16: Tamoxifen metabolism was not perturbed by Cyp2d-KD1 siRNA.  Endoxifen 
was the primary metabolite detected.   
 
In summary, one siRNA construct can be used to repress the expression of number of 
homologous Cyp subfamily members. However, repressing the expression of several 
Cyps may have unexpected consequences for the expression of other Cyps that were not 
targeted by the siRNA as Cyp2d10 expression was significantly increased following the 
knockdown of other CYP2D members.  Transfection of primary mouse hepatocytes with 
6uM of Cyp2d-KD1 and TransIT-TKO was successfully able to knockdown the 
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expression of multiple Cyp2ds, however, the knockdown cells were still able to 
metabolized the selected compounds. We hypothesize that more time is necessary for the 
loss of Cyp2d isoforms, and for proper loss of protein expression we would need to 
incubate the cells in the siRNA for 48 hours or more.  Because primary hepatocytes 
continually lose the expression of most CYPs including Cyp2d isoforms (Karen M. et al., 
2009), this may preclude the use of siRNAs to functionally knockdown Cyp2d expression 
in monolayer primary hepatocyte cultures.   
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CONCLUSIONS 
 
Multiple Cyp2ds isoforms (Cyp2d10, Cyp2d11, Cyp2d22 and Cyp2d26) were expressed 
in detectable level in mouse primary hepatocytes, and this made it a possible in vitro 
model system to study Cyp2ds function(s). Knockdown the expression of multiple 
Cyp2ds was the main objective of this study by using a single construct of siRNA 
(preferentially Cyp2d-KD1).  Optimizing the transfection condition for the highest 
knockdown efficiency was achieved by using siRNA at concentration of 6µM and 
TransIT-TKO transfection reagent.  Scrambled treated hepatocytes did not have any 
effect on Cyp2d expression and therefore comparing the level of expression of Cyp2d-
KD1 treated hepatocytes to that of scrambled treated hepatocytes was a valid comparison. 
Since hepatocytes represent the most appropriate model for the evaluation of integrated 
drug metabolism that contributes to estimate human specific toxicity, this knockdown 
model was used to test for metabolizing efficacy of known CYP2D6 substrates.  
However, the loss of CYP2D activity overtime in vitro and/or species differences in 
enzyme activity may explain the failure of the knowdown model to show any differences 
in the metabolite profile or quantification after incubation of tamoxifen, testosterone, or 
the luminogenic CYP2D6 substrate compared to controls cells.  The overall objectives 
from this work are to identify a simple method to manipulate an in vitro model, 
knockdown the expression of multiple CYP2D and conduct functional drug metabolism 
studies.   
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In the liver, drug metabolism is a multistep process starting with phase I reactions 
(oxidation, reduction, and hydrolysis) then phase II reaction (conjugation). Therefore, the 
liver is the critical organ when studying the drug pharmacokinetics. CYP2D is a crucial 
set of phase I enzymes and plays a central role in the metabolism of many xenobiotic and 
endogenous compounds (Nelson et al., 1996). Moreover, several drug-metabolizing 
enzymes including CYP2D6 have been shown to be polymorphic (Ingelman-Sundberg, 
2002; Miners et al., 2002) indicating that genetic polymorphism can cause differences in 
the drug pharmacokinetics. Induction and inhibition of drug metabolizing enzymes are 
causes of drug interaction. Serious drug interactions involving P450 have been reported 
(Dresser et al., 2000; Niemi et al., 2003).  For example, Terfenadine and cisapride were 
withdrawn from the market because of the QT prolongation caused by the inhibition of 
CYP3A4 by a coadministered drug (e.g. triazole antifungal agent).  Prediction of adverse 
drug reactions (ADR) is critical in drug development.  
 
In the preclinical stage, human-derived sources or experimental animals are common 
models to perform the pharmacokinetics. Human liver microsomes and human 
hepatocytes in primary culture are used nowadays as tools during drug development. 
Human liver microsomes have an advantage; microsomes can be stored for a few years 
without the loss of enzyme activities but the problem is it cannot be used to evaluate any 
induction potencies. Human primary hepatocytes express all the drug metabolizing 
enzymes, but the there is a huge loses of enzyme activity overtime and the availability of 
donor material is limited and their large variability between donors (Schaeffner et al., 
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2005; Gomez-Lechon et al., 2003; Rodrigues and Rushmore, 2002).  Because of 
disadvantages and limitations of using human models, experimental animals, in vitro 
animal models and humanized transgenic lines are the most widely used models to 
perform the pharmacokinetics studies recently. An in vitro mouse hepatocyte system 
might be an alternative to the human systems, especially if the metabolic competence is 
preserved (Jae et al, 2011). Since the complete sequence of the mouse genome is 
published (Waterston et al., 2002) and chimeric mouse models are widely used, primary 
mouse hepatocytes are usable for the purpose of performing drug metabolism studies 
(Karen et al 2009). Furthermore, rodent systems have been used for years so there is 
historic data that can be used to estimate whether particular metabolite pathways are 
relevant to human health.   
 
In this study, two mouse cell lines (HEPA1C1C7 and RΙΙΙPrΙ) and mouse primary 
hepatocytes were characterized for expression of mouse CYP2Ds. Cyp2d22 is the only 
isoform detected in RΙΙΙPrΙ cell line. HEPA1C1C7 did not show any expression of the 
nine CYP2D isoforms. Mouse primary hepatocytes showed expression of Cyp2d10, 
Cyp2d11, Cyp2d22 and Cyp2d26 using specific primers for PCR and real time PCR. 
Also western blot analysis showed detectable level of Cyp2d protein in the primary 
culture when Cyp2d specific polyclonal antibody was used. This makes primary culture 
to be the in vitro model system of choice and the one we used in studying Cyp2d 
expression function(s) and their role in metabolizing xenobiotics and endobiotics 
compounds. However, primary culture has a short duration of survival and every step 
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towards a more gentle handling and transfection are critical to maintain cell vitality. 
Another drawback of primary culture is the huge lose of enzyme activity in a time-
dependent manner (Kienhuis et al., 2007; Karen M. et al. 2009) and information about 
stability of liver specific functions in mice is scarce (Karen et al, 2009). In conclusion, 
primary hepatocytes have advantages of expressing CYP2D; however, this in vitro model 
has some limitations. 
 
In mouse there are at least nine isoforms of CYP2Ds (Nelson et al., 2004). Those 
isoforms have great sequence similarities and there is a belief of having redundant 
interfering functions. This interfering function could make the humanized mouse model 
less useful for studying the function of CYP2D6 in polymorphic individuals. Knocking 
out those nine isoforms is expensive and may not be a practical approach while knocking-
down CYP2Ds could be done to study the function of mouse CYP2Ds and eliminate their 
redundant interfering function in the humanized mouse model. The discovery of small 
interference RNA has provided novel avenues to enhance gene function studies as well as 
drug target discovery (Romano et al., 1992; Tang et al., 2003). 
 
Using a single construct of siRNA to knockdown the expression of multiple Cy2ds was 
the main objective in this study. After looking at the highest sequence similarity between 
the CYP2D nine isoforms, two siRNA constructs were designed in this study (Cyp2d-
KD1 and Cyp2d-KD2) to knockdown multiple CYP2Ds at once. The results showed that 
Cyp2d-KD1 was successfully able to knockdown multiple CYP2Ds.  On the other hand 
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Cyp2d-KD2 induces Cyp2d10 expression, presumably as a compensatory mechanism to 
overcome the down regulation of the other isoforms.  
 
The transcriptional regulation of CYP2D in mice remains unknown.  In terms of gene 
regulation of CYP2D, several liver-enriched transcription factors and expressed factors 
are responsible for the constitutive expression of the CYP2D subfamily in humans and 
rodents (Lee et al., 1994; Yokomori et al., 1995a, b; Cairns et al., 1996; Mizuno et al., 
2003). Previous studies showed that HNF4α controls constitutive levels of expression of 
the CYP2D6 gene.  Moreover, CYP2D6 gene expression was down-regulated by the 
depletion of HNF4 α using adenovirus- mediated antisense targeting that selectively 
diminishes HNF4 α content in human hepatocytes, (Javier et al., 2001;  Jover et al., 
2001). This indicates that further studies may be still needed to explain the compensatory 
induction of Cyp2d10 in the Cyp2d-KD2 knockdown model.  
 
Our data indicates that Cyp2d-KD1 is the siRNA of choice to knockdown multiple 
CYP2Ds at once. Also, using siRNA at a concentration of 6µM was the best tolerated 
dose without triggering an interferon response or significant cell toxicity. Interferon 
(IFN) activation and induction of the cellular dsRNA-dependent protein kinase (PKR) 
response in mammalian cells can be a possible drawback of the use of higher dose of 
RNAi, which in turn inhibits all protein expression. Therefore, siRNAs were designed to 
be <~30 bp to avoid the PKR response and avoid nonspecific effects on gene silencing 
(Caplen et al. 2001; Elbashir et al. 2001). While using lower siRNA concentration (2µM) 
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was not able to effectively repress multiple CYP2Ds; higher concentration of siRNA (12 
µM) and using combination of multiple siRNA caused obvious cell toxicity and 
inconsistent cellular response in the transfected hepatocytes.  
 
Primary mouse hepatocytes were shipped to us 24hrs after isolation. The cells had a 90% 
confluence, displayed a classical polygonal shape and demonstrate a successful 
monolayer adhesion in the coated collagen surface of the 6-well plate. When TransIT-
siQUEST transfection reagent, or multiple siRNA, or higher siRNA dose (12µM) was 
used, cell debris was observed, the cells looked dead, and the RNA extracted was of poor 
quality.   Optimizing the transfection efficiency by comparing three different transfection 
reagents showed that TransIT-TKO from Mirus Bio was the transfection reagent of choice 
with about 90% transfection efficiency and minimum cell toxicity.  This provides 
pharmacologists and toxicologists with information that may be helpful when performing 
future siRNA studies with primary hepatocytes.   
 
Foreign chemicals as well as endogenous compound are subject to metabolism by a 
number of xenobiotic and endobiotics metabolizing enzymes to facilitate their 
elimination. CYP2D enzymes are among the most important enzymes responsible for the 
oxidative metabolism of a diverse range of substrates (Guengerich, 2003). Thus the last 
objective in this study is to test the possibility of using primary hepatocytes as in vitro 
model system in metabolism study. Three CYP2D substrates were chosen to test our 
model; testosterone, tamoxifen and luminogenic CYP2D6 substrate. In mouse 
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testosterone is metabolized by Cyp2d9, Cyp2d10 and Cyp2d11 to 16 -
hydroxytestosteron (Wong et al., 1989) so the sterio- and regio-specific hydroxylation of 
testosterone and the contribution of CYP2D to this effect could be investigated using our 
model. A testosterone hydroxylase activity in knockdown and scrambled treated 
hepatocytes was measured by thin layer chromatography (TLC).  The second tested 
substrate was P450-Glo™ CYP2D6 enzyme kits, where a luminogenic CYP2D6 
substrate was incubated with S9 fraction from tested cells. The third substrate was 
tamoxifen, selective estrogen receptor modulator used for treatment and prevention of 
breast cancer (Eberling et al., 2004). In humans, CYP2D6 is involved in tamoxifen 
metabolism and 4-OH-tamoxifen and endoxifen are important active metabolites of 
tamoxifen (Stearns et al., 2003; Lim et al., 2006). The data from metabolism study 
showed that there was no metabolites difference of testosterone, luminogenic CYP2D6 
substrate, or tamoxifen between knockdown and wild type hepatocytes. This might be 
explained by the remaining functional CYP2Ds protein inside the hepatocytes. To 
maintain as much as CYP2D activity, transfection was done only for 24hrs, during this 
period; about 50-70% of CYP2Ds mRNA was degraded by siRNA-KD1. However, the 
previously translated CYP2Ds protein may be still remaining and functioning in the cells 
and may be still able to metabolize those substrates.    
 
For the P450-Glo™ CYP2D6 enzyme kits, because of species differences, the mouse 
Cyp2d activity may be different from CYP2D6 and it is possible that murine Cyp2d 
isoforms could not metabolize the substrate.  Moreover, primary culture has high level of 
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esterase activity that affects the substrate stability.  A potential explanation of the 
inability of our knockdown in vitro model system to show significant difference from the 
wild type cells in metabolizing the tested substrates is the marked differences in CYP2D 
between humans and experimental animals (Masubuchi et al., 1997). Significant species 
differences exist between rodents and humans in expression and catalytic activity 
between human CYP2D6 and rodent Cyp2d (Bogaards et al., 2000). This data 
demonstrates that the search for a better or known mouse CYP2D specific substrate is 
important in evaluating the impaired metabolic profile in the in vitro knockdown model 
system.     
  
In conclusion, for the first time, multiple CYP2D were successfully down-regulated in 
the mouse primary hepatocytes in an in vitro model using a single siRNA construct. One 
potential application of this method is to determine and quantify the role of specific CYPs 
in the metabolism of individual drugs.  A second could be to study potential 
compensatory mechanisms and interactions between CYPs.  Third, a long-term potential 
goal or application of this work is applying the CYP2D-KD1 siRNA to the in vivo model 
system (humanized mouse model) to knockdown the expression of mouse CYP2Ds. This 
would be valuable application to reduce the redundant interfering function of mouse 
CYP2Ds in those models.  Thus this would be a promising application in the 
pharmaceutical industry to validate the humanized model system in studying the 
CYP2D6 function in polymorphic individuals and avoid the possible ADR in those 
individuals.  
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Another interesting finding in this study is that Cyp2d10 was over expressed when 
Cyp2d-KD2 was used, indicating that Cyp2d10 is inducible. Future directions toward 
understanding of the mechanism by which Cyp2ds are regulated and could help elucidate 
which transcription factors are needed. However, the loss of Cyp2d9 expression in vitro, 
and gradual loss of CYP2D over time suggesting that more efforts are still needed to 
develop alternative cellular models that maintain the basal level of CYP2D expression in 
vitro. 3D culture could be a possibility.   
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